Boehringer Ingelheim’s London AI hub deepens Big Pharma’s data colonialism in global health research

Indigenous knowledge systems view health as holistic and interconnected, contrasting with Boehringer’s reductionist, data-driven approach that fragments biological processes into algorithmic inputs. The AI centre’s reliance on Western biomedical paradigms risks erasing traditional diagnostic methods, such as pulse reading in Ayurveda or plant-based remedies, which have millennia of empirical validation. Moreover, the extraction of Indigenous genetic data for AI training without Free, Prior and Informed Consent (FPIC) mirrors historical patterns of biopiracy, such as the patenting of neem or turmeric by Western corporations. The framing of AI as 'neutral' ignores how it perpetuates epistemic violence by privileging corporate-controlled knowledge over community-based wisdom.

The launch of Boehringer’s AI centre echoes colonial-era pharmaceutical exploitation, where Western firms conducted clinical trials in the Global South without equitable returns, as seen in the case of Pfizer’s 1996 Nigerian meningitis trial. The shift to AI-driven drug discovery replicates this dynamic, with corporations now monopolising not just physical samples but also the digital derivatives of patient data. Historical precedents like the 19th-century patenting of quinine by European firms from Indigenous South American knowledge systems highlight the recurring pattern of knowledge extraction. The AI hub’s location in London—a former imperial hub—further underscores the continuity of extractive practices under a new technological guise.

In contrast to Boehringer’s centralised AI model, many non-Western health systems prioritise decentralised, community-based data governance, such as India’s Ayushman Bharat Digital Mission or Rwanda’s community health worker networks. African traditional healers, who serve 80% of the population in some regions, utilise oral knowledge systems that are incompatible with the datafication required by AI models, yet their insights could revolutionise drug discovery if integrated ethically. The AI centre’s focus on 'efficiency' overlooks the cultural value of time in healing practices, where patience and ritual are integral to treatment. Cross-cultural comparisons reveal that Western biomedical models often pathologise symptoms that Indigenous systems view as imbalances requiring holistic intervention, leading to misaligned AI training datasets.

AI in drug discovery promises to accelerate target identification and reduce costs, but its efficacy is contingent on the quality and representativeness of training data, which are often biased toward Western populations. Studies show that AI models trained on predominantly European genetic data perform poorly on non-European cohorts, exacerbating health disparities in diagnostics and treatment. The AI centre’s reliance on proprietary datasets risks reinforcing confirmation bias, as algorithms may prioritise drug targets aligned with corporate profit margins over unmet medical needs in marginalised communities. Furthermore, the lack of transparency in AI decision-making obscures potential errors, such as false positives in molecular docking simulations, which could lead to costly clinical trial failures.

Artistic and spiritual traditions often frame health as a balance between body, mind, and environment, a holistic view that contrasts with the mechanistic reductionism of AI-driven drug discovery. For example, Traditional Chinese Medicine’s concept of 'qi' or Ayurveda’s 'doshas' are incommensurable with the binary logic of machine learning algorithms, yet they offer nuanced frameworks for understanding disease. The AI centre’s sterile, data-centric environment overlooks the role of creativity in scientific discovery, such as the serendipitous breakthroughs in penicillin or artemisinin, which emerged from non-linear, intuitive processes. Moreover, the spiritual dimension of healing—such as the placebo effect—is systematically excluded from AI models, reducing health to a quantifiable output.

If unchecked, Boehringer’s AI hub could accelerate a future where 80% of global health data is controlled by 5 corporations, leading to a monopolistic drug discovery ecosystem that prioritises blockbuster drugs over orphan diseases. Scenario modelling suggests that by 2035, AI-driven drug discovery could reduce R&D costs by 30%, but only for conditions prevalent in wealthy markets, deepening the '10/90 gap' where 90% of global health research funding targets 10% of diseases. The centre’s location in London—a global financial hub—positions it to attract speculative capital, risking a bubble in 'AI pharma' stocks that could collapse if regulatory scrutiny increases. Conversely, a cooperative model where AI centres are publicly owned and data is shared under open licenses could democratise drug discovery, as seen in the EU’s proposed European Health Data Space.

Marginalised communities, including Indigenous groups, low-income patients, and researchers from the Global South, are systematically excluded from the design and governance of Boehringer’s AI centre, despite being the primary data sources. The absence of ethical frameworks like the Nagoya Protocol or the UN Declaration on the Rights of Indigenous Peoples in the project’s design ensures that these communities have no recourse to challenge data exploitation. Local researchers in Africa or Latin America, who could provide critical insights into regional disease burdens, are relegated to data collection roles rather than decision-making positions. The AI centre’s narrative of 'innovation' thus serves as a smokescreen for a new form of digital colonialism, where the voices of those most affected by health disparities are silenced.